# Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

> **NCT03281538** · PHASE3 · COMPLETED · sponsor: **Cara Therapeutics, Inc.** · enrollment: 288 (actual)

## Conditions studied

- Uremic Pruritus

## Interventions

- **DRUG:** CR845

## Key facts

- **NCT ID:** NCT03281538
- **Lead sponsor:** Cara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-14
- **Primary completion:** 2020-02-11
- **Final completion:** 2020-02-11
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03281538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03281538, "Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03281538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*